Australia Markets open in 6 hrs 13 mins

Verizon Communications Inc. (VZ)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
44.79+0.11 (+0.25%)
As of 01:47PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close44.68
Bid44.81 x 1800
Ask44.81 x 1000
Day's range44.65 - 45.06
52-week range43.77 - 56.20
Avg. volume20,219,051
Market cap188.029B
Beta (5Y monthly)0.38
PE ratio (TTM)8.42
EPS (TTM)5.32
Earnings date19 Apr 2022 - 25 Apr 2022
Forward dividend & yield2.56 (5.54%)
Ex-dividend date07 July 2022
1y target est53.57
  • GlobeNewswire

    Unfold and behold! The Galaxy Z series is coming to Verizon, the network America relies on

    Pre-order today with deals you want on the network you need New and existing customers can get $800 off the new Samsung Galaxy Z Flip4 or Galaxy Z Fold4 with select trade-in on a qualified 5G Unlimited plan1Plus, when you switch, get a $200 Verizon eCard after you sign up2Pre-order your 128GB Galaxy Z Flip4 or 256GB Galaxy Z Fold4 on Verizon today and get upgraded to the next storage tier for free NEW YORK, Aug. 10, 2022 (GLOBE NEWSWIRE) -- The Samsung Galaxy Z Flip4 and Galaxy Z Fold4 are comin

  • Motley Fool

    Should Retirees Sell This Dividend Stock After a Dud Quarter?

    Here's why Verizon should remain an excellent dividend stock for retirees. Verizon delivered a Q2 report that some might call mediocre. Operating results confirmed some trouble under the hood and subscriber growth fell off the cliff in Verizon's wireless segment.

  • GlobeNewswire

    Verizon Business Selected to Transform Astellas Pharma’s Global Network Infrastructure

    Digital Transformation seen as critical enabler in delivering improved patient outcomes and future growthTOKYO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Verizon Business has been selected to manage Astellas Pharma Inc’s (Astellas) global network infrastructure. The network transformation will enable Astellas to harness advanced technologies to help reduce drug development timelines, healthcare costs and drive new revenue opportunities for the Japanese pharmaceutical multinational. Headquartered in Toky